AHR Earnings Prediction
The chart below shows how AHR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AHR sees a +0.56% change in stock price 10 days leading up to the earnings, and a +6.67% change 10 days following the report. On the earnings day itself, the stock moves by -0.45%. This data can give you a slight idea of what to expect for the next quarter's release.
AHR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
523.81M
12.83%
3.81%
Gross Margin
19.12%
14.49%
2.96%
Operating Margin
7.13%
129.26%
13.54%
Net Margin
-0.59%
-57.55%
-201.72%
EPS
-0.03
-66.67%
-250.00%
No Data Available
AHR Earnings Analysis
American Healthcare REIT, Inc. Corporation (AHR.N) Earnings Conference Call
Positive
Same-Store NOI Growth: 1. Strong Same-Store NOI Growth: Total portfolio same-store NOI grew by 17% year-over-year in Q3 2024, with the Trilogy segment achieving 22.6% growth and the SHOP segment reaching 61.8% growth compared to Q3 2023.
Capital Raising Success: 2. Successful Capital Acquisition: The company raised approximately $471.2 million in gross proceeds from a follow-on public common stock offering, which facilitated the acquisition of a 24% interest in Trilogy for about $258 million and allowed for a $194 million paydown on lines of credit.
2024 NOI Growth Guidance: 3. Increased Guidance for 2024: The company raised its same-store NOI growth guidance for the full year 2024 to a range of 15% to 17%, up 300 basis points at the midpoint from previous guidance, reflecting strong organic growth and accretive transactions.
Increased NFFO Guidance: 4. Improved Financial Metrics: The normalized funds from operations (NFFO) guidance for 2024 was increased significantly to a range of $1.40 to $1.43 per fully diluted share, representing an increase of $0.165 at the midpoint from prior guidance.
Debt to EBITDA Improvement: 5. Enhanced Balance Sheet: The company's debt to EBITDA ratio improved to 5.1 times as of September 30, 2024, a reduction of nearly 1.5 times from the end of Q1 2024, indicating a stronger financial position and capacity for future growth.
Negative
Occupancy Rate Decline: 1. Declining Occupancy Rates: Trilogy's occupancy was approximately 87.6% as of November 1, 2024, indicating a stagnation in growth compared to previous quarters.
Operating Expenses Concerns: 2. Increased Operating Expenses: Despite strong revenue growth, there are concerns that inflation could lead to increased operating expenses, which may outpace revenue growth in the future.
Debt Financing Risks: 3. High Leverage Ratio: The company's debt to EBITDA ratio stands at 5.1 times, which, while improved, still indicates a reliance on debt financing that could pose risks in a rising interest rate environment.
Asset Streamlining Strategy: 4. Noncore Asset Dispositions: The company is actively selling noncore assets, including outpatient medical buildings, which suggests a need to streamline operations and improve financial health rather than a focus on growth.
External Growth Reliance: 5. Dependence on External Growth: The company has indicated that future growth will rely heavily on external acquisitions, which may be challenging in a competitive market and could lead to dilution if funded through equity offerings.
AHR FAQs
How does AHR typically perform around its earnings report dates?
Is American Healthcare REIT, Inc. (AHR) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AHR Earning Call Sentiment
American Healthcare REIT, Inc. (AHR) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
AHR.N
1.61%Positive
The earnings call highlights strong financial performance, with significant growth in same-store NOI and NFFO, improved debt metrics, and strategic acquisitions. The increased guidance for 2024 further supports a positive outlook. Although the follow-on stock offering could be a concern, the proceeds were used for debt reduction, enhancing financial health. The Q&A reveals optimism about occupancy trends and Trilogy's operational excellence, despite some concerns over labor and inflation. Overall, the positive financial metrics and strategic growth initiatives suggest a positive stock price movement in the near term.
